D. Begic

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

M. Kudo, R. Finn, B. Sangro, 2019, Annals of Oncology.

LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

M. Kudo, T. Yau, R. Finn, 2020 .

CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).

M. Kudo, R. Finn, B. Sangro, 2020 .

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

M. Kudo, J. Furuse, G. Abou-Alfa, 2021, The Lancet. Oncology.

Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype.

B. Tsuji, C. von Eiff, D. Begic, 2009, The Journal of antimicrobial chemotherapy.

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

R. Xu, H. Pan, Yanqiao Zhang, 2017, BMC Cancer.

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Jianming Xu, L. Shen, R. Xu, 2017, BMC Cancer.

Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial

M. Kudo, R. Finn, R. Kelley, 2022, Cancer Research.